The company's focus is on discovering and developing products that treat gastrointestinal infections and related diseases where current therapies have limitations. Optimer has two late-stage anti-infective product candidates, fidaxomicin and Pruvel, as well as other products in its portfolio. The company aims to make a positive impact on society by developing hospital specialty products that significantly improve patients' lives and reduce the burden of disease. Optimer's antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) is an example of the company's commitment to developing medicines that make a difference.